Jonathan R Dry
Affiliation: AstraZeneca R and D
- Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry
Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
Cancer Res 70:2264-73. 2010..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...